Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer
- 1 May 1992
- journal article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 35 (5) , 471-476
Abstract
Sixty-six consecutive patients who underwent curative resection for rectal cancer were studied prospectively to evaluate the roles of sequential carcinoembryonic antigen (CEA), tissue plasminogen activator (TPA), and carcinomatous antigen 19-9 (Ca 19-9) determinations in the early diagnosis of resectable recurrences. Thirty-three recurrences were detected between 6 and 42 months. CEA, TPA, and Ca 19-9 showed a sensitivity of 72.7 percent, 78.8 percent, and 60.1 percent, respectively, and a specificity of 60.6 percent, 60.6 percent, and 87.9 percent, respectively. In 23 cases the rise in the value of CEA and/or TPA and/or Ca 19-9 was the first sign of recurrences, and the diagnosis was established later by clinical methods. In this group, the lead time was two months for liver metastases and four months for disseminated metastases. As far as the relationship between localization of recurrence and marker level increase is concerned, of 16 hepatic metastases CEA, TPA, and Ca 19-9 showed a sensitivity of 94 percent (P less than 0.05), 69 percent, and 62 percent, respectively. Of six patients with local recurrences, CEA, TPA, and Ca 19-9 showed a sensitivity of 50 percent, 100 percent (P less than 0.05), and 83.3 percent, respectively. Of three patients with peritoneal carcinomatosis, CEA, TPA (P less than 0.05), and Ca 19-9 showed a sensitivity of 0 percent, 100 percent, and 0 percent, respectively. No significant differences were reported among the three markers according to multiple metastases and metachronous polyps. Fourteen patients (42.4 percent) underwent surgical treatment for recurrent disease, and eight of them (57 percent) showed a resectable disease, for a total resectability rate of 24.2 percent. The findings of our study indicate that a follow-up program based on CEA, TPA, and Ca 19-9 assays is related to an early diagnosis and a good resectability rate for both local and metastatic recurrences from rectal cancer.Keywords
This publication has 17 references indexed in Scilit:
- Reoperation directed by carcinoembryonic antigen level: The importance of a thorough preoperative evaluationThe American Journal of Surgery, 1988
- Follow-up of colorectal cancer resected for cureDiseases of the Colon & Rectum, 1987
- CEA-Directed Second-look Surgery in the Asymptomatic Patient after Primary Resection of Colorectal CarcinomaAnnals of Surgery, 1985
- Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bankInternational Journal of Cancer, 1984
- Is CEA analysis of value in screening for recurrences after surgery for colorectal carcinoma?Diseases of the Colon & Rectum, 1983
- Role of carcinoembryonic antigen in detection of asymptomatic disseminated disease in colorectal carcinoma.BMJ, 1983
- Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancerJournal of Clinical Immunology, 1982
- Postoperative screening of patients with carcinoma of the colonDiseases of the Colon & Rectum, 1981
- Specific Antigen in Serum of Patients with Colon CarcinomaScience, 1981
- Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigenJournal of Surgical Research, 1980